^Chalon P, Vita N, Kaghad M, Guillemot M, Bonnin J, Delpech B, Le Fur G, Ferrara P, Caput D (1996). „Molecular cloning of a levocabastine-sensitive neurotensin binding site”. FEBS Lett. 386 (2-3): 91—4. PMID8647296. doi:10.1016/0014-5793(96)00397-3.
^Vita N, Oury-Donat F, Chalon P, Guillemot M, Kaghad M, Bachy A, Thurneyssen O, Garcia S, Poinot-Chazel C, Casellas P, Keane P, Le Fur G, Maffrand JP, Soubrie P, Caput D, Ferrara P (1999). „Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells”. Eur J Pharmacol. 360 (2-3): 265—72. PMID9851594. doi:10.1016/S0014-2999(98)00678-5.
Mazella J; Botto JM; Guillemare E; et al. (1996). „Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain.”. J. Neurosci. 16 (18): 5613—20. PMID8795617.CS1 одржавање: Експлицитна употреба et al. (веза)
Martin S, Vincent JP, Mazella J (2002). „Recycling ability of the mouse and the human neurotensin type 2 receptors depends on a single tyrosine residue.”. J. Cell. Sci. 115 (Pt 1): 165—73. PMID11801734.
Leyton J, Garcia-Marin L, Jensen RT, Moody TW (2002). „Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells.”. Eur. J. Pharmacol. 442 (3): 179—86. PMID12065070. doi:10.1016/S0014-2999(02)01539-X.
Somaï S, Gompel A, Rostène W, Forgez P (2002). „Neurotensin counteracts apoptosis in breast cancer cells.”. Biochem. Biophys. Res. Commun. 295 (2): 482—8. PMID12150975. doi:10.1016/S0006-291X(02)00703-9.
Holst B; Holliday ND; Bach A; et al. (2005). „Common structural basis for constitutive activity of the ghrelin receptor family.”. J. Biol. Chem. 279 (51): 53806—17. PMID15383539. doi:10.1074/jbc.M407676200.CS1 одржавање: Експлицитна употреба et al. (веза)
„Neurotensin Receptors: NTS2”. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Архивирано из оригинала 03. 03. 2016. г.